🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects

    Arbutus Biopharma Corp

    Chronic hepatitis B virus Infection

    phase 1 other active

    1 trial

  2. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1076986 in Healthy Adults.

    NEUROCRINE BIOSCIENCES INC

    Movement disorders

    phase 1 other active

    1 trial

  3. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1117570 in Healthy Adults

    NEUROCRINE BIOSCIENCES INC

    Neurological and neuropsychiatric conditions

    phase 1 other active

    1 trial

  4. Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients

    Lacuna Pharma Pty Ltd

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease

    phase 1 other active

    1 trial

  5. Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

    Boehringer Ingelheim

    Plaque psoriasis

    phase 1 other active

    1 trial

  6. Segesterone Acetate and Ethinyl Estradiol

    TherapeuticsMD

    Women

    phase 1 small molecule completed

    1 trial

  7. Segesterone Acetate and Ethinyl Estradiol

    TherapeuticsMD

    Contraception

    phase 1 small molecule completed

    1 trial

  8. Selinexor

    Karyopharm Therapeutics Inc

    Refractory Multiple Myeloma

    phase 1 small molecule active

    1 trial

  9. Selinexor

    Karyopharm Therapeutics Inc

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  10. Selinexor

    Karyopharm Therapeutics Inc

    Soft Tissue Sarcoma

    phase 1 small molecule completed

    1 trial

  11. Selinexor

    Karyopharm Therapeutics Inc

    Liposarcoma

    phase 1 small molecule terminated

    1 trial

  12. Selinexor

    Karyopharm Therapeutics Inc

    Amyloid

    phase 1 small molecule terminated

    1 trial

  13. Selinexor

    Karyopharm Therapeutics Inc

    Colorectal Neoplasm

    phase 1 small molecule terminated

    1 trial

  14. Selinexor

    Karyopharm Therapeutics Inc

    Prolymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  15. Selinexor Pill

    Karyopharm Therapeutics Inc

    Hepatocellular Carcinoma

    phase 1 small molecule terminated

    1 trial

  16. Shigella sonnei 53G

    United Therapeutics Europe Ltd

    Healthy

    phase 1 mab completed

    1 trial

  17. Shigella sonnei 53G

    United Therapeutics Europe Ltd

    Shigellosis

    phase 1 mab active

    2 trials

  18. Simvastatin

    United Therapeutics Europe Ltd

    Recurrent Acute Pancreatitis

    phase 1 small molecule active

    1 trial

  19. Simvastatin

    Aurinia Pharmaceuticals

    Drug-drug Interaction

    phase 1 small molecule completed

    1 trial

  20. Single Ascending Dose of SAB-176

    SAB Biotherapeutics

    PHA1A

    phase 1 small molecule active

    1 trial

  21. Single dose oral bioequivalence study of Cladribine 10 mg Tablets and Mavenclad® 10 mg tablets (Cladribine) in healthy adult human subjects under fed conditions

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers.

    phase 1 other active

    1 trial

  22. Small RNA sequencing

    Inhibitor Therapeutics

    Fertility

    phase 1 gene therapy completed

    1 trial

  23. Sodium phenylbutyrate

    ZEVRA THERAPEUTICS, INC.

    Combined D,L-2-hydroxyglutaric Aciduria

    phase 1 small molecule active

    1 trial

  24. Solriamfetol 150 mg Oral Tablet

    Axsome Therapeutics

    Narcolepsy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources